Transfer of Development and Sales Rights to Arotec in Australia

On June 10, Dong-A ST announced that it has signed a license-out agreement with Arotec for cenobamate (brand name: Xcopri), an epilepsy treatment, covering the Australian and New Zealand markets.


Dong-A ST Signs License-Out Agreement for Cenobamate Epilepsy Treatment in Australia and New Zealand View original image

Under this agreement, Dong-A ST will transfer the rights for development and sales of cenobamate in Australia and New Zealand to Arotec. Arotec will be responsible for local regulatory approval and commercialization, while Dong-A ST will manufacture and supply the finished product.


In January 2024, Dong-A ST signed a licensing-in agreement for cenobamate with SK Biopharmaceuticals, covering 30 countries including Korea, East and Southeast Asia, Russia, Australia, New Zealand, and Türkiye. Dong-A ST obtained domestic marketing approval for cenobamate in November last year and is currently undergoing the reimbursement listing process.


Cenobamate works by inhibiting sodium channels involved in excitatory signal transmission and by enhancing the function of GABAA receptors, thereby regulating the hyperexcitable state of neurons and restoring the balance between excitatory and inhibitory signals. According to the company, pivotal multinational clinical trials in adult patients with partial-onset seizures demonstrated a significant reduction in seizure frequency and a complete seizure-free rate among those administered Xcopri, proving its remarkable efficacy.


Arotec is one of the leading local pharmaceutical companies in Australia's prescription drug market, with a distribution and sales network that spans both Australia and New Zealand. The company operates a dedicated marketing team in the central nervous system (CNS) field and sells a variety of epilepsy treatments.



Jaehoon Jung, CEO of Dong-A ST, stated, "This agreement marks our first overseas license-out case utilizing a medicine that was introduced from an external source, and it will be an important milestone in expanding Dong-A ST’s global business. We will continue to expand our presence in overseas markets and strengthen our global competitiveness based on diverse global business models and partnerships."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing